Home › Funds › ACT Capital Partners, L.P. › KYTX
ACT Capital Partners, L.P. position in KYTX
KYVERNA THERAPEUTICS INC · Health Care
ACT Capital Partners, L.P. reported holding 40,000 shares of KYTX (KYVERNA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$272K, representing 0.18% of its reported portfolio and ranking #44 among its reported holdings. ACT Capital Partners, L.P. first reported this position in Q3 2026.
Last updated: 2026-11-07 · Source: SEC EDGAR Form 13F-HR
How ACT Capital Partners, L.P.'s KYTX position evolved
ACT Capital Partners, L.P. first disclosed a stake in KYTX in Q3 2026 at 40,000 shares (US$272K).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 40.00K | $272.00K | New |
About KYTX and 13F data
KYTX (KYVERNA THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in KYTX — the largest reported positions include GordonMD Global Investments LP (US$37.8M), GILEAD SCIENCES, INC. (US$28.1M), Bain Capital Life Sciences Investors, LLC (US$25.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYTX
- GordonMD Global Investments LP 4.24M sh · $37.82M · Q2 2026
- GILEAD SCIENCES, INC. 4.13M sh · $28.06M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 2.88M sh · $25.71M · Q2 2026
- AIGH Capital Management LLC 2.80M sh · $24.91M · Q2 2026
- Insight Holdings Group, LLC 989.05K sh · $8.81M · Q2 2026
- Propel Bio Management, LLC 883.20K sh · $7.87M · Q2 2026
- MBB PUBLIC MARKETS I LLC 614.48K sh · $5.47M · Q2 2026
More on ACT Capital Partners, L.P.
FAQ
How long has ACT Capital Partners, L.P. held KYTX?
ACT Capital Partners, L.P. has disclosed KYTX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is ACT Capital Partners, L.P.'s current position in KYTX?
As of Q3 2026, ACT Capital Partners, L.P. holds 40.00K shares of KYTX (KYVERNA THERAPEUTICS INC), valued at $272.00K, representing 0.18% of its reported portfolio and ranking #44.
Has ACT Capital Partners, L.P. been buying or selling KYTX?
In the latest 13F filing (Q3 2026), ACT Capital Partners, L.P. newly opened its position in KYTX.
Which other funds hold KYTX?
Other major institutional holders of KYTX include GordonMD Global Investments LP, GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.